Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.

N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.

2.

Vitamin E and nonalcoholic fatty liver disease.

Pacana T, Sanyal AJ.

Curr Opin Clin Nutr Metab Care. 2012 Nov;15(6):641-8. doi: 10.1097/MCO.0b013e328357f747. Review.

3.

Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.

Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H.

J Pediatr Gastroenterol Nutr. 2009 May;48(5):587-96. doi: 10.1097/MPG.0b013e31818e04d1. Review.

PMID:
19412008
4.

[Steatosis and steatohepatitis in diabetic patient].

Hůlek P, Dresslerová I.

Vnitr Lek. 2011 Apr;57(4):364-7. Review. Czech.

PMID:
21612059
5.

Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Corey KE, Rinella ME.

Dig Dis Sci. 2016 May;61(5):1387-97. doi: 10.1007/s10620-016-4083-8. Epub 2016 Mar 4. Review.

6.

State of the art: treatment of nonalcoholic steatohepatitis.

Pearlman M, Loomba R.

Curr Opin Gastroenterol. 2014 May;30(3):223-37. doi: 10.1097/MOG.0000000000000060. Review.

PMID:
24717764
7.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Lomonaco R, Sunny NE, Bril F, Cusi K.

Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0. Review.

PMID:
23329465
8.

Nonalcoholic fatty liver disease: a systematic review.

Rinella ME.

JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. Review. Erratum in: JAMA. 2015 Oct 13;314(14):1521.

PMID:
26057287
9.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

10.

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Stein LL, Dong MH, Loomba R.

Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16. Review.

PMID:
19921118
11.

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

Mahady SE, Webster AC, Walker S, Sanyal A, George J.

J Hepatol. 2011 Dec;55(6):1383-90. doi: 10.1016/j.jhep.2011.03.016. Epub 2011 Apr 14. Review.

PMID:
21703200
12.

New treatments for nonalcoholic fatty liver disease.

Harrison SA.

Curr Gastroenterol Rep. 2006 Feb;8(1):21-9. Review.

PMID:
16510031
13.

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.

Smith BW, Adams LA.

Nat Rev Endocrinol. 2011 May 10;7(8):456-65. doi: 10.1038/nrendo.2011.72. Review.

PMID:
21556019
14.

[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].

Korenaga M, Kawaguchi K, Korenaga K, Uchida K, Sakaida I.

Nihon Rinsho. 2006 Jun;64(6):1157-64. Review. Japanese.

PMID:
16768125
15.

Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.

Ahmed A, Wong RJ, Harrison SA.

Clin Gastroenterol Hepatol. 2015 Nov;13(12):2062-70. doi: 10.1016/j.cgh.2015.07.029. Epub 2015 Jul 27. Review.

PMID:
26226097
16.

Nonalcoholic fatty liver disease: new treatments.

Hardy T, Anstee QM, Day CP.

Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175. Review.

17.

Thiazolidinediones and the liver in humans.

Yki-Järvinen H.

Curr Opin Lipidol. 2009 Dec;20(6):477-83. doi: 10.1097/MOL.0b013e3283321d37. Review.

PMID:
19779336
18.

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. Review.

PMID:
17253544
19.

Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.

Polyzos SA, Mantzoros CS.

Metabolism. 2016 Sep;65(9):1297-306. doi: 10.1016/j.metabol.2016.05.013. Epub 2016 May 27. Review.

PMID:
27506737
20.

Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.

Ganesh S, Rustgi VK.

Clin Liver Dis. 2016 May;20(2):351-64. doi: 10.1016/j.cld.2015.10.009. Epub 2016 Feb 19. Review.

PMID:
27063274

Supplemental Content

Support Center